**Abstract**

**Background:** Accumulation of beta amyloid (Aβ) in the brain and carriage of the apolipoprotein E (APOE) ɛ4 allele have both been reported to independently and interactively linked with greater neurodegeneration, cognitive decline and incipient Alzheimer's disease (AD). However, as most studies have observed these effects over 18-months or more, the effect of Aβ and ɛ4 on cognitive decline over 12-months remains unknown. Detecting rapid cognitive decline is critical for monitoring efficacy over shorter periods. In this study we examined the effects of Aβ and ɛ4 on rates of cognitive change assessed using the CANTAB over 12-months in aMCI patients.

**Methods:** 145 participants with aMCI were recruited from the European-ADNI study. They were aged between 55--90, had a ≥1SD deficit in episodic memory and fulfilled a clinical diagnosis of aMCI. Participants underwent cognitive assessment using the CANTAB at baseline, 6 and 12 months and lumbar punctures for CSF measurement of Abeta42. Individuals were divided into Aβ+ (CSF-POS) (\<550pg/ml)(n=55) and Aβ- (CSF-NEG)(\>550pg/ml)(n=90).

**Results:** Aβ+ aMCI individuals (relative to Aβ-) showed faster decline in paired associates learning (PAL) (p=0.02, ES=0.4) over 12 months. Aβ+ aMCI individuals who were APOE ɛ4 carriers (compared to non- carriers) had a greater decline in PAL (p\<0.01, ES=0.6). No other cognitive domain including attention and executive function were affected by Aβ positivity and/or APOE ɛ4 carriage.

**Conclusions:** Aβ+ individuals with aMCI declined at a faster rate over 12-months on episodic memory. The decline in memory in Aβ+ individuals with aMCI was exacerbated by the presence of the APOE ɛ4 allele. Other cognitive domains including psychomotor speed, attention and executive function were not affected Aβ positivity and/or APOE e4 carriage. These findings suggest a memory decline in Aβ+ individuals with aMCI can be detected as early as 12 months using the CANTAB PAL task of episodic memory.
